

Press Release

BSE: 506690 NSE: UNICHEMLAB Reuters: UNLB.BO Bloomberg: UN@IN

Mumbai, March 3, 2010

UNICHEM LABORATORIES LIMITED HAS BEEN GRANTED EU GMP CERTIFICATE FOR 12 API'S

The IRISH MEDICINES BOARD has granted EU GMP for the following 12 API's manufactured at our Roha plant.

- 1) AMLODIPINE BESILATE
- 2) AMLODIPINE MALEATE
- 3) BENDROFLUMETHIAZIDE
- 4) BISOPROLOL FUMARATE
- 5) BRIMONIDINE TARTARATE
- 6) BUPREMORPHINE HYDROCHLORIDE
- 7) CLONIDINE HYDROCHLORIDE
- 8) DONEPEZIL HYDROCHLORIDE
- 9) HYDROCHLOROTHIAZIDE
- 10) METRONIDAZOLE
- 11) TIZANIDINE HYDROCGLORIDE
- 12) MELOXICAM

With this approval the Company can market its approved API's in the whole of Europe.

About Unichem Laboratories Limtied.

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com.

Contacts:

 Mr. K Subharaman
 Mr. Rakesh Parikh
 Mr. M Gundu Rao

 Tel: +912266888404
 Tel: +912266888414
 Tel: +912266888380

 Cell: +919833031121
 Cell: +919892925555
 Cell: +919820228944

🖂 : subharamank@unichemindia.com subharamank@unichemi

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

-000-

